Olpasiran heart scan study for high Lp(a) patients
Part of Heart & circulation clinical trials.
This study tests if a medication called olpasiran can lower a type of fat in your blood called Lp(a), which is linked to heart problems. You take the medicine or a placebo and get a special heart scan to see changes in your arteries.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 35 and 80 years old.
- You must have a blood test showing Lp(a) level of 200 nmol/L or higher.
- You must have a heart scan showing plaque in at least one major artery.
- You must have had a heart attack (type 1) or a procedure (like a stent) to open a blocked artery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if olpasiran can lower a type of cholesterol called Lp(a) to help prevent a first major heart attack, stroke, or other heart problems. It is for people at higher risk due to risk factors or early signs of artery disease, but who have not yet had a heart attack or stroke.
This study tests two new drugs, alone and together, to lower a type of cholesterol called Lp(a) that increases heart disease risk. You may qualify if you have high Lp(a) and your LDL cholesterol is still high despite current treatment.
This study tests whether a new medicine called lepodisiran can shrink plaque in heart arteries for adults with high Lp(a) (a type of cholesterol linked to heart disease) who have had a heart event or are at serious risk. The trial uses CT scans to monitor changes in your arteries.
This program provides early access to a study drug called olpasiran, which may help lower cholesterol. Doctors can request it for patients who have no other treatment options and cannot join a clinical trial.
This study uses a heart CT scan to look for early signs of heart disease in first-degree relatives of people with high or low Lp(a). It aims to find hidden risks before symptoms start.
This study tests an oral medication called HRS-5346 to see if it can lower a type of fat in the blood called lipoprotein(a), which is linked to heart disease. If you have high Lp(a) and are at risk for heart problems, this trial may help reduce that risk.
Hear when a new Cardiovascular Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.